- Home
- AARD vs NVCT Comparison
AARD vs NVCT Comparison
Compare AARD & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- NVCT
- Stock Information
- Founded
- AARD 2017
- NVCT 2020
- Country
- AARD United States
- NVCT United States
- Employees
- AARD N/A
- NVCT N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- AARD Health Care
- NVCT Health Care
- Exchange
- AARD Nasdaq
- NVCT Nasdaq
- Market Cap
- AARD 154.9M
- NVCT 184.9M
- IPO Year
- AARD 2025
- NVCT 2022
- Fundamental
- Price
- AARD $13.68
- NVCT $8.07
- Analyst Decision
- AARD Strong Buy
- NVCT Strong Buy
- Analyst Count
- AARD 5
- NVCT 3
- Target Price
- AARD $33.00
- NVCT $17.00
- AVG Volume (30 Days)
- AARD 84.2K
- NVCT 179.4K
- Earning Date
- AARD 08-14-2025
- NVCT 08-05-2025
- Dividend Yield
- AARD N/A
- NVCT N/A
- EPS Growth
- AARD N/A
- NVCT N/A
- EPS
- AARD N/A
- NVCT N/A
- Revenue
- AARD N/A
- NVCT N/A
- Revenue This Year
- AARD N/A
- NVCT N/A
- Revenue Next Year
- AARD N/A
- NVCT N/A
- P/E Ratio
- AARD N/A
- NVCT N/A
- Revenue Growth
- AARD N/A
- NVCT N/A
- 52 Week Low
- AARD $4.88
- NVCT $4.44
- 52 Week High
- AARD $19.58
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- NVCT 46.65
- Support Level
- AARD N/A
- NVCT $7.70
- Resistance Level
- AARD N/A
- NVCT $8.39
- Average True Range (ATR)
- AARD 0.00
- NVCT 0.40
- MACD
- AARD 0.00
- NVCT 0.06
- Stochastic Oscillator
- AARD 0.00
- NVCT 50.40
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.